Skip to main content
. 2016 Sep 14;22(34):7718–7726. doi: 10.3748/wjg.v22.i34.7718

Table 1.

Ligands for orally targeted drug delivery in inflammatory bowel disease

Ligand Delivery system Effect Ref.
Lectin PLGA Exhibited a much higher binding and selectivity to inflamed tissue compared to plain NPs [54]
TfR antibodies Liposomes Exhibited mucopenetration and a 4-fold increase in uptake by inflamed colon tissues [58]
CD98 antibodies PEG–urocanic acid-chitosan Approximately 24% of colonic macrophages were found to have taken up the targeted NPs within 12 h of administration [66]
Mannose Branched polyethylenimine 29.5% of the NPs were internalized by colon macrophages [26]
Galactose Trimethyl chitosan-cysteine Cellular uptake in activated macrophages was significantly higher for Galactose trimethyl chitosan-cysteine/TPP NPs compared to trimethyl chitosan-cysteine/TPP NPs [75]
F4/80 Ab Fab' Poly(lactic acid)-poly(ethylene glycol) block copolymer Improved DSS-induced colitis in vivo, and higher therapeutic efficacy was obtained using Fab'-bearing NPs compared to non-conjugated NPs [77]
Amphiphilic hyaluronic acid Decylamine Budesonide loaded HANPs demonstrated higher anti-inflammatory effect on IL-8 and TNF-α secretion in inflamed cell model compared to the same dose of free drug [78]

TfR: Transferrin receptor; PLGA: Polylactic-co-glycolic acid.